Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.